This is a working overview of thymosin beta-4, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-23 and is reviewed periodically as new material appears.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
| Property | Value | Notes |
|---|---|---|
| Reported sequence | Ac-LKKTETQ | Described in most listings as the actin-binding region of thymosin beta-4 |
| Reported molecular weight | Approximately 889 Da | Value shifts with the stated sequence; compare against the certificate of analysis |
| Parent protein length | 43 amino acids | Thymosin beta-4; the fragment covers only a small part of it |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Trade-style names rather than formal nomenclature |
| Formal monographs | Not established | Labeling conventions differ by supplier and region |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
https://doi.org/10.1016/j.cell.2024.10.042 Schat, K. A., Kaspers, B., & Kaiser, P. (2014). Structure of the Avian Lymphoid System. In I. Olah, N. Nagy & L. Vervelde (Eds.), Avian Immunology (2nd ed., pp. 11-44). Academic Press.
Vortioxetine is well-absorbed when taken orally and has an oral bioavailability of 75%. It is systemically detectable after a single oral dose by 0.781 hours. Peak levels of vortioxetine are reached within 7 to 11 hours post-dose with single or multiple doses. Steady-state levels of vortioxetine are generally reached within 2 weeks of administration, with 90% of individuals reaching 90% of steady state after 12 days of administration. Steady-state peak levels of vortioxetine with doses of 5, 10, and 20 mg/day were 9, 18, and 33 ng/mL, respectively. The accumulation index of vortioxetine (area-under-the-curve levels after a single dose versus at steady state) is 5 to 6. A loading dose given intravenously has been found to achieve steady-state levels more rapidly with oral vortioxetine therapy. The pharmacokinetics of vortioxetine are known to be linear and dose proportional over a range of 2.5 to 75 mg for single doses and 2.5 to 60 mg for multiple doses. Food has no influence on the pharmacokinetics of vortioxetine. The apparent volume of distribution of vortioxetine is large and ranges from 2,500 to 3,400 L after single or multiple doses of 5 to 20 mg vortioxetine, with extensive extravascular distribution. The plasma protein binding of vortioxetine is approximately 98 or 99%, with about 1.25 ± 0.48% free or unbound. Vortioxetine is extensively metabolized by oxidation via cytochrome P450 enzymes and subsequent glucuronidation via UDP-glucuronosyltransferase.
=== Freeze drying (lyophilized) === Donkey milk can be freeze-dried to preserve the biological quality of the milk, and so preserve its nutritional, functional, and cosmetic properties. This is possible because in freeze drying the milk is frozen and brought under vacuum at low temperatures. During this process, the water is removed by sublimation. The result is approximately ten percent of dry matter that is called lyophilized (or freeze-dried) donkey milk. This powder is easy to reconstitute. The lyophilized product has to be packaged without any oxygen. It has a shelf life of two years. Normally it is produced from pasteurized donkey milk so it is ready to use. Analysis of freeze-dried donkey's milk has demonstrated that the natural colour, flavours, nutrients, and bioactive substances of fresh donkey milk are retained. Spray-drying is another way to dry products, in which the milk is heated and vitamins and other important bioactive substances may get lost. In contrast, Freeze-drying does not require chemical preservatives and can be either consumed directly or re-hydrated easily. However, this method for is costly, and is practiced only by a few companies. This product is easy to find in Italy, where it was for the first time put on the market.
2025: Datchinamurthy Kataiah, a Malaysian drug trafficker hanged for smuggling 44.96g of diamorphine on 25 September 2025. 2025: Pannir Selvam Pranthaman, a Malaysian drug trafficker hanged on 8 October 2025 for smuggling 51.84g of diamorphine. 2026: Omar Bin Yacob Bamadhaj, a Singaporean was hanged on 16 April 2026 for trafficking 1,009.1g of cannabis in July 2018
This one is to be put on first, is also worn overnight, and exerts a basic pressure of 20 mmHg or less. Also, it keeps the wound dressing in place. A second stocking, often brown, sometimes black, achieves a pressure of 20–30 mmHg and is applied over the other stocking during the daytime. Intermittent pneumatic compression devices may be used, but it is not clear that they are superior to simple compression dressings. It is not clear if interventions that aim to help people adhere to compression therapy are effective. More research is needed in this field.
Sources: en.wikipedia.org
3D food printing is the process of manufacturing food products using a variety of additive manufacturing techniques. Most commonly, food grade syringes hold the printing material, which is then deposited through a food grade nozzle layer by layer. The most advanced 3D food printers have pre-loaded recipes on board and also allow the user to remotely design their food on their computers, phones or some IoT device. The food can be customized in shape, color, texture, flavor or nutrition, which makes it very useful in various fields such as space exploration and healthcare.
== History and etymology == Eosin was named by its inventor Heinrich Caro after the nickname (Eos) of a childhood friend, Anna Peters. It was commercialized (mainly for the textile industry) in 1874, in the same year when it was invented.
== Fare == Moe's offers various types of food on its menu, including burritos, tacos, quesadillas, nachos, salads, stacks, burrito bowls, and house-made seasonal salsas. Ingredients can be added or subtracted from the standard entree for customization. Every order comes with chips and salsa on the side.
== Economy == The gross domestic product (GDP) of the state was 229.5 billion euros in 2018, accounting for 8.7% of German economic output. GDP per capita adjusted for purchasing power was 33,700 euros or 112% of the EU27 average in the same year. The GDP per employee was 100% of the EU average. Agriculture, strongly weighted towards the livestock sector, has always been a very important economic factor in the state. The north and northwest of Lower Saxony are mainly made up of coarse sandy soil that makes crop farming difficult and therefore grassland and cattle farming are more prevalent in those areas. Lower Saxony is home, in 2017, to one in five of Germany's cattle, one in three of the country's pigs, and 50% of its hens. Wheat, potatoes, rye, and oats are among the state's present-day arable crops. Towards the south and southeast, extensive loess layers in the soil left behind by the last ice age allow high-yield crop farming. One of the principal crops there is sugar beet. Consequently, the Land has a big food industry, mainly organised in small and medium-sized enterprises (SME). Big players are Deutsches Milchkontor and PHW Group (biggest German poultry farmer and producer). Mining has also been an important source of income in Lower Saxony for centuries. Silver ore became a foundation of notable economic prosperity in the Harz Mountains as early as the 12th century, while iron mining in the Salzgitter area and salt mining in various areas of the state became another important economic backbone.
Sources: en.wikipedia.org
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.
No. Thymosin beta-4 is a protein of 43 amino acids, while TB-500 is described as a short fragment of it. The two differ in size, structure, and the range of interactions each can support.
Naming for research peptides is not centrally coordinated, so vendors set their own labels and specifications. Differences in stated sequence, molecular weight, or purity documentation usually trace back to those independent labeling choices.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.